WHO ICTRP trial
Swinburne Three-dose Psilocybin Assisted Psychotherapy (3PAP): a clinical trial…
ACTRN12623000667617 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Recruiting
Key facts
| Trial ID | ACTRN12623000667617 |
|---|---|
| Public title | Swinburne Three-dose Psilocybin Assisted Psychotherapy (3PAP): a clinical trial of 2 vs 3 doses of psilocybin-assisted psychotherapy vs psychotherapy with placebo for Treatment-Resistant Depression |
| Scientific title | Efficacy and safety of two versus three high dose psilocybin-assisted therapy sessions in comparison to a placebo for treatment resistant major depressive disorder (TR-MDD): A double blind, 3-arm Phase 2b randomised controlled trial |
| Primary sponsor | Swinburne University of Technology, Hawthorn |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | Australia |
| Conditions | Treatment-Resistant Depression; Treatment-Resistant Depression;Mental Health - Depression |
| Interventions | There will be two intervention arms and one control arm. Arm 1: 3 dose-sessions of 25 mg oral psilocybin + psychotherapy Arm 2: 2 dose-sessions of 25 mg oral psilocybin + psychotherapy, followed by 1 dose-session of oral inactive placebo +… |
| Registration date | Jun 21, 2023 |
| Target size | 160 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: